Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGFBR1 | P36897 | 13/20 | 0.45 |
| ▸ | TGFBR2 | P37173 | 6/20 | 0.45 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.40 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.40 |
| ▸ | AHR | P35869 | 1/20 | 0.36 |
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.33 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.33 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.33 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.33 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9104900 | 0.83 | AHR (0.56) | TGFBR1TGFBR2CYP11B1CYP11B2AHR | |
| SCHEMBL9105396 | 0.77 | CYP11B1 (0.46) | CYP11B1CYP11B2AHRPDE10A | |
| SCHEMBL9104569 | 0.74 | PDE10A (0.54) | CYP11B1CYP11B2AHRPDE10A | |
| SCHEMBL9104524 | 0.73 | AHR (0.41) | TGFBR1TGFBR2CYP11B1CYP11B2AHR | |
| Hydrochloric Acid SCHEMBL16341275 | 0.73 | PDE10A (0.53) | CYP11B1CYP11B2AHRPDE10A | |
| SCHEMBL9107552 | 0.72 | CYP11B2 (0.44) | TGFBR1CYP11B1CYP11B2AHRPDE10A | |
| SCHEMBL9108923 | 0.71 | HSD17B2 (0.48) | AHRPDE10APIK3CAPIK3CG | |
| SCHEMBL9106396 | 0.70 | AHR (0.50) | CYP11B1CYP11B2AHRPDE10APIK3CD | |
| SCHEMBL9109108 | 0.70 | SMN1; SMN2 (0.46) | CYP11B1CYP11B2AHRPDE10A | |
| SCHEMBL9104774 | 0.69 | JAK2 (0.48) | CYP11B1CYP11B2PIK3CDPIK3CAPIK3CG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2649070-B1 | TRIAZOLOPYRIDINE COMPOUNDS | HOFFMANN LA ROCHE (CH) | 2014-09-17 | — | — | EP | disclosed |
| EP-2649070-B1 | TRIAZOLOPYRIDINE COMPOUNDS | HOFFMANN LA ROCHE (CH) | 2014-09-17 | — | — | EP | disclosed |
| EP-2649070-A1 | TRIAZOLOPYRIDINE COMPOUNDS | F.HOFFMANN-LA ROCHE AG (CH) | 2013-10-16 | — | — | EP | disclosed |
| US-8349824-B2 | Triazolopyridine compounds | HOFFMANN-LA ROCHE INC. (US) | 2013-01-08 | — | — | US | disclosed |
| US-8349824-B2 | Triazolopyridine compounds | HOFFMANN-LA ROCHE INC. (US) | 2013-01-08 | — | — | US | disclosed |
| US-8349824-B2 | Triazolopyridine compounds | HOFFMANN-LA ROCHE INC. (US) | 2013-01-08 | — | — | US | disclosed |
| WO-2012076430-A1 | TRIAZOLOPYRIDINE COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2012-06-14 | — | — | WO | disclosed |
| WO-2012076430-A1 | TRIAZOLOPYRIDINE COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2012-06-14 | — | — | WO | disclosed |
| US-20120142665-A1 | TRIAZOLOPYRIDINE COMPOUNDS | HOFFMANN-LA ROCHE INC. | 2012-06-07 | — | — | US | disclosed |
| US-20120142665-A1 | TRIAZOLOPYRIDINE COMPOUNDS | HOFFMANN-LA ROCHE INC. | 2012-06-07 | — | — | US | disclosed |
| US-20120142665-A1 | TRIAZOLOPYRIDINE COMPOUNDS | HOFFMANN-LA ROCHE INC. | 2012-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120142665-A1 | TRIAZOLOPYRIDINE COMPOUNDS | PDE5A, PDE3A, PDE3B | TGFBR1 499/4885TGFBR2 924/4885CYP11B1 478/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.